- Home
- KEY vs NBIX Comparison
KEY vs NBIX Comparison
Compare KEY & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEY
- NBIX
- Stock Information
- Founded
- KEY 1825
- NBIX 1992
- Country
- KEY United States
- NBIX United States
- Employees
- KEY N/A
- NBIX N/A
- Industry
- KEY Major Banks
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KEY Finance
- NBIX Health Care
- Exchange
- KEY Nasdaq
- NBIX Nasdaq
- Market Cap
- KEY 15.7B
- NBIX 12.8B
- IPO Year
- KEY N/A
- NBIX 1996
- Fundamental
- Price
- KEY $17.25
- NBIX $118.46
- Analyst Decision
- KEY Buy
- NBIX Buy
- Analyst Count
- KEY 19
- NBIX 24
- Target Price
- KEY $17.44
- NBIX $163.91
- AVG Volume (30 Days)
- KEY 9.6M
- NBIX 789.6K
- Earning Date
- KEY 10-17-2024
- NBIX 10-30-2024
- Dividend Yield
- KEY 4.72%
- NBIX N/A
- EPS Growth
- KEY N/A
- NBIX 89.41
- EPS
- KEY 0.01
- NBIX 3.29
- Revenue
- KEY $4,852,000,000.00
- NBIX $2,119,500,000.00
- Revenue This Year
- KEY N/A
- NBIX $25.96
- Revenue Next Year
- KEY $12.24
- NBIX $16.41
- P/E Ratio
- KEY $3,339.79
- NBIX $35.94
- Revenue Growth
- KEY N/A
- NBIX 26.69
- 52 Week Low
- KEY $9.50
- NBIX $103.63
- 52 Week High
- KEY $17.94
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- KEY 57.87
- NBIX 49.83
- Support Level
- KEY $16.91
- NBIX $111.14
- Resistance Level
- KEY $17.94
- NBIX $120.11
- Average True Range (ATR)
- KEY 0.41
- NBIX 2.12
- MACD
- KEY 0.07
- NBIX 1.45
- Stochastic Oscillator
- KEY 65.08
- NBIX 81.99
About KEY KeyCorp
With assets of over $180 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.